Business
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
BOSTON, April 30, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) campaign for AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets), the first and only treatment specifically approved by the U.S. Food and Drug Administration (FDA) for adult patients with KRAS-mutated recurrent LG
About this update from Verastem, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1920,"height":1080,"url":"https://media.zenfs.com/en/business-wire.com/185ba394284b68cba23866e5c07167ea"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mAmQ4zc2ZGbnJxhQmwsUrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MA--/https://media.zenfs.com/en/business-wire.com/185ba394284b68cba23866e5c07167ea","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/oS06.qeE93In6g5FpXwsGA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUw/https://media.zenfs.com/en/business-wire.com/185ba394284b68cba23866e5c07167ea","width":1200,"height":675}}},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":445,"url":"https://media.zenfs.com/en/business-wire.com/2984a0134bd88ac22cce93fb3fe54cde"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7q6Sb8J1j.dBw09Cgg174Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg5MA--/https://media.zenfs.com/en/business-wire.com/2984a0134bd88ac22cce93fb3fe54cde","width":480,"height":445}}},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1200,"height":200,"url":"https://media.zenfs.com/en/business-wire.com/e179afd4e2388690bc938a94e288a797"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XiT75f9uzm3UyQ5fuEeYBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MA--/https://media.zenfs.com/en/business-wire.com/e179afd4e2388690bc938a94e288a797","width":960,"height":160},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_LfDyZZIzOPLor6.uPcYXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/e179afd4e2388690bc938a94e288a797","width":1200,"height":200}}},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":368,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/cc4caad47ce3ddc147c05b01a29374aa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/c6Ec3WyObTT9LydyBzyHAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTkyMA--/https://media.zenfs.com/en/business-wire.com/cc4caad47ce3ddc147c05b01a29374aa","width":368,"height":480}}},{"t...